secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2026-10-01T11:30:19+00:00
Accession:  0001193125-26-409819
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Kyntra Bio appoints Andrew Singer to board, Maykin Ho resigns; CEO Wettig signs new severance agreement
--------------------------------------------------------------------------------

- Andrew E. Singer, MBA was appointed as a Class III director and Audit Committee member effective October 1, 2026; his term expires in 2029.
- Maykin Ho, Ph.D. resigned from the board effective September 30, 2026 after serving since December 2018, including on the Audit Committee; no disagreement cited.
- CEO Thane Wettig entered a new Change in Control and Severance Agreement on September 30, 2026, with a three-year term ending October 2, 2029; no material changes to pay.
- Singer has 25+ years in biotech finance, led West Coast biotech investment banking at Credit Suisse, was Epizyme CFO, and advised on over $50 billion in transactions.
- Kyntra Bio common stock trades on Nasdaq under KYNB; it focuses on oncology and rare disease therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000119312526409819/0001193125-26-409819-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000119312526409819/kynb-20260930.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-409819

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer